Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.39)
# 265
Out of 5,180 analysts
88
Total ratings
54.43%
Success rate
18.72%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Downgrades: Hold | $56 → $53 | $52.77 | +0.45% | 5 | Mar 31, 2026 | |
| IVA Inventiva | Initiates: Buy | $13 | $5.31 | +144.82% | 1 | Mar 19, 2026 | |
| SEPN Septerna | Maintains: Buy | $34 → $35 | $24.55 | +42.57% | 2 | Mar 11, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $44 → $55 | $49.64 | +10.80% | 6 | Mar 4, 2026 | |
| BIIB Biogen | Maintains: Hold | $190 → $193 | $183.38 | +5.25% | 6 | Feb 9, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $84 → $92 | $66.64 | +38.06% | 5 | Feb 3, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $88 → $110 | $104.43 | +5.33% | 4 | Jan 5, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $116 | $86.40 | +34.26% | 6 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $580 → $640 | $532.55 | +20.18% | 2 | Nov 19, 2025 | |
| INCY Incyte | Reiterates: Hold | $79 → $93 | $94.53 | -1.62% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $13.73 | +9.25% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $31.44 | +59.03% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $940 → $812 | $776.58 | +4.56% | 8 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $21 → $11 | $11.02 | -0.18% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $11.71 | +113.49% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $961.57 | +7.95% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $214.85 | +1.00% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $28.29 | +13.11% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $31.92 | +56.64% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.52 | +3,464.36% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $5.21 | +187.91% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $15.71 | +129.15% | 1 | Jul 31, 2024 |
Terns Pharmaceuticals
Mar 31, 2026
Downgrades: Hold
Price Target: $56 → $53
Current: $52.77
Upside: +0.45%
Inventiva
Mar 19, 2026
Initiates: Buy
Price Target: $13
Current: $5.31
Upside: +144.82%
Septerna
Mar 11, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $24.55
Upside: +42.57%
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $44 → $55
Current: $49.64
Upside: +10.80%
Biogen
Feb 9, 2026
Maintains: Hold
Price Target: $190 → $193
Current: $183.38
Upside: +5.25%
Cytokinetics
Feb 3, 2026
Maintains: Buy
Price Target: $84 → $92
Current: $66.64
Upside: +38.06%
Protagonist Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $88 → $110
Current: $104.43
Upside: +5.33%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $116
Current: $86.40
Upside: +34.26%
Madrigal Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $580 → $640
Current: $532.55
Upside: +20.18%
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $94.53
Upside: -1.62%
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $13.73
Upside: +9.25%
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $31.44
Upside: +59.03%
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $776.58
Upside: +4.56%
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $11.02
Upside: -0.18%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $11.71
Upside: +113.49%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $961.57
Upside: +7.95%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $214.85
Upside: +1.00%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $28.29
Upside: +13.11%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $31.92
Upside: +56.64%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.52
Upside: +3,464.36%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $5.21
Upside: +187.91%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $15.71
Upside: +129.15%